Diarylureas as Antitumor Agents

Abstract

The diarylurea is a scaffold of great importance in medicinal chemistry as it is present in numerous heterocyclic compounds with antithrombotic, antimalarial, antibacterial, and anti-inflammatory properties. Some diarylureas, serine-threonine kinase or tyrosine kinase inhibitors, were recently reported in literature. The first to come into the market as an anticancer agent was sorafenib, followed by some others. In this review, we survey progress over the past 10 years in the development of new diarylureas as anticancer agents.

Keywords

• diarylureas
• antitumor agents
• bis-aryl ureas
• hepatocellular carcinoma (HCC)
• renal cell carcinoma (RCC)
• gastrointestinal stromal tumors (GISTs)